Creative Planning
LXRX icon

Creative Planning’s Lexicon Pharmaceuticals LXRX Stock Holding History

Creative Planning’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-400
Closed -$7K – 2931
2017
Q2 		$7K Sell
400
-982
-71% -$15.2K ﹤0.01% 3830
2017
Q1 		$20K Buy
1,382
+1,000
+262% +$14.8K ﹤0.01% 3132
2016
Q4 		$5K Buy
382
+56
+17% +$899 ﹤0.01% 3959
2016
Q3 		$6K Sell
326
-1,387
-81% -$22.3K ﹤0.01% 3812
2016
Q2 		$25K Buy
1,713
+1,500
+704% +$20.3K ﹤0.01% 2639
2016
Q1 		$3K Buy
213
+71
+50% +$744 ﹤0.01% 3815
2015
Q4 		$2K Sell
142
-1,500
-91% -$18.4K ﹤0.01% 4043
2015
Q3 		$18K Buy
+1,642
New +$17.9K ﹤0.01% 2804
2015
Q2 		– Sell
-2,971
Closed -$20K – 2181
2015
Q1 		$20K Hold
2,971
– – ﹤0.01% 2713
2014
Q4 		$19K Sell
2,971
-929
-24% -$7.49K ﹤0.01% 2693
2014
Q3 		$38K Buy
3,900
+2,143
+122% +$22.9K ﹤0.01% 2103
2014
Q2 		$20K Buy
1,757
+186
+12% +$2K ﹤0.01% 2486
2014
Q1 		$19K Buy
+1,571
New +$20.1K ﹤0.01% 2409
2013
Q3 		– Sell
-143
Closed -$2K – 3289
2013
Q2 		$2K Buy
+143
New +$2.17K ﹤0.01% 2827

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Creative Planning's LXRX Position: Q3 2017 in Review

Creative Planning sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 400 shares — an estimated $7K sold.

Creative Planning first reported a position in LXRX in Q2 2013 and held it in 14 quarters. The position peaked at $38K in Q3 2014. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Creative Planning reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 400 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $7K.
  • Creative Planning first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Creative Planning's Lexicon Pharmaceuticals position peaked at $38K in Q3 2014.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.